US-based cell therapy technology developer Kytopen picked up $30m on Tuesday in a series A round featuring Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria Real Estate Equities.
Northpond Ventures led the oversubscribed round, which also attracted Horizons Ventures, Mass Ventures, The Engine and private investors Michael Chambers and John Ballantyne.
Kytopen is working on scalable technology that facilitates the non-viral manufacturing of cell therapies in a matter of days rather than the weeks required by current methods.
The series A capital has been allocated to accelerating partnerships that will allow Kytopen to bring its first products into clinical testing and speed up commercialisation activities. It had previously raised $3.1m in funding in November 2020, according to a regulatory filing.
The company disclosed $3.6m in seed funding from The Engine, Horizons Ventures and unnamed angel investors in May 2019. It was one of the first seven startups to receive funding from The Engine in 2017, with the size of the investment undisclosed.
The original version of this article appeared on our sister site, Global University Venturing.
